MariMed (OTCMKTS:MRMD) Upgraded at Zacks Research

Zacks Research upgraded shares of MariMed (OTCMKTS:MRMD) from a strong sell rating to a hold rating in a research note released on Thursday,Zacks.com reports.

Separately, Ventum Cap Mkts cut shares of MariMed from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to MarketBeat, MariMed currently has an average rating of “Moderate Buy”.

MariMed Trading Down 4.3%

OTCMKTS:MRMD opened at $0.09 on Thursday. The business’s 50-day moving average is $0.10 and its two-hundred day moving average is $0.11. The firm has a market capitalization of $35.60 million, a PE ratio of -2.25 and a beta of 1.04. MariMed has a 12 month low of $0.07 and a 12 month high of $0.23. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.06 and a quick ratio of 0.35.

MariMed (OTCMKTS:MRMD) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $40.76 million during the quarter, compared to analyst estimates of $42.15 million. MariMed had a negative net margin of 11.36% and a negative return on equity of 14.67%.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.